Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

威罗菲尼 医学 安慰剂 阿替唑单抗 内科学 肿瘤科 危险系数 彭布罗利珠单抗 外科 不利影响 转移性黑色素瘤 癌症 免疫疗法 置信区间 病理 替代医学
作者
Ralf Gutzmer,Daniil Stroyakovskiy,Helen J Gogas,Caroline Robert,Karl D. Lewis,Проценко Светлана Анатольевна,Rodrigo Perez Pereira,Thomas Eigentler,Piotr Lukasz Rutkowski,Лев Вадимович Демидов,Georgy Moiseevich Manikhas,Yibing Yan,Kuan-Chieh Huang,Anne R. Uyei,Virginia A. McNally,Grant A. McArthur,Paolo A. Ascierto
出处
期刊:The Lancet [Elsevier BV]
卷期号:395 (10240): 1835-1844 被引量:692
标识
DOI:10.1016/s0140-6736(20)30934-x
摘要

Summary

Background

IMspire150 aimed to evaluate first-line combination treatment with BRAF plus MEK inhibitors and immune checkpoint therapy in BRAFV600 mutation-positive advanced or metastatic melanoma.

Methods

IMspire150 was a randomised, double-blind, placebo-controlled phase 3 study done at 112 institutes in 20 countries. Patients with unresectable stage IIIc–IV, BRAFV600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group). In cycle 1, all patients received vemurafenib and cobimetinib only; atezolizumab placebo was added from cycle 2 onward. Randomisation was stratified by lactate dehydrogenase concentration and geographical region. Blinding for atezolizumab was achieved by means of an identical intravenous placebo, and blinding for vemurafenib was achieved by means of a placebo tablet. The primary outcome was investigator-assessed progression-free survival. This trial (ClinicalTrials.gov, NCT02908672) is ongoing but no longer recruiting patients.

Findings

Between Jan 13, 2017, and April 26, 2018, 777 patients were screened and 514 were enrolled and randomly assigned to the atezolizumab group (n=256) or control group (n=258). At a median follow-up of 18·9 months (IQR 10·4–23·8), progression-free survival as assessed by the study investigator was significantly prolonged with atezolizumab versus control (15·1 vs 10·6 months; hazard ratio [HR] 0·78; 95% CI 0·63–0·97; p=0·025). Common treatment-related adverse events (>30%) in the atezolizumab and control groups were blood creatinine phosphokinase increased (51·3% vs 44·8%), diarrhoea (42·2% vs 46·6%), rash (40·9%, both groups), arthralgia (39·1% vs 28·1%), pyrexia (38·7% vs 26·0%), alanine aminotransferase increased (33·9% vs 22·8%), and lipase increased (32·2% vs 27·4%); 13% of patients in the atezolizumab group and 16% in the control group stopped all treatment because of adverse events.

Interpretation

The addition of atezolizumab to targeted therapy with vemurafenib and cobimetinib was safe and tolerable and significantly increased progression-free survival in patients with BRAFV600 mutation-positive advanced melanoma.

Funding

F Hoffmann–La Roche and Genentech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
粒粒发布了新的文献求助10
刚刚
共享精神的应助被yy采纳,获得10
刚刚
传奇3的应助被柴六斤采纳,获得10
2秒前
晚霞跌落星河的应助被MADAO采纳,获得30
2秒前
2秒前
翟思宇发布了新的文献求助10
3秒前
didida发布了新的文献求助10
3秒前
cc完成签到,获得积分10
3秒前
3秒前
Doran_luffy完成签到,获得积分10
4秒前
pkfsp发布了新的文献求助10
4秒前
水煮电吹风的应助被Chenzhs采纳,获得10
4秒前
5秒前
人生海海发布了新的文献求助10
5秒前
6秒前
Zhb完成签到,获得积分10
6秒前
wangjundong完成签到,获得积分20
7秒前
小安的应助被yu采纳,获得10
7秒前
7秒前
8秒前
8秒前
KOKORO完成签到,获得积分10
8秒前
简单老师发布了新的文献求助10
9秒前
Firsterchao发布了新的文献求助30
10秒前
10秒前
10秒前
10秒前
DW的应助被衣锦夜行采纳,获得10
11秒前
慕青的应助被学术智子采纳,获得10
11秒前
12秒前
leekk完成签到,获得积分10
12秒前
a念完成签到,获得积分10
12秒前
酷波er的应助被魏伯安采纳,获得10
12秒前
yy发布了新的文献求助10
13秒前
岁御无相完成签到 ,获得积分10
13秒前
14秒前
lll发布了新的文献求助10
14秒前
14秒前
CipherSage的应助被errui采纳,获得10
15秒前
冷静冷风完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651